Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 10 April 2018

Indication(s)

Mycophenolate mofetil Teva is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

ESICM LIVES Highlights

ESICM LIVES Highlights

ESICM LIVES Congress 2018: Bringing you the latest news and insights from the 31st ESICM LIVES Congress, 20–24 October 2018 Paris, France.

Load more

Related Content

Journal articles

Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.

This review aims to provide appropriate guidance that will minimize the impact of adverse events and help to maximize the utility of this agent in patients with advanced renal cell carcinoma.

Added 7 months ago

Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients.

The aim of this retrospective study was to determine the frequency and timing of trastuzumab cardiotoxicity and its risk factors in real-world setting.

Added 8 months ago

Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.

Clinical trials and meta-analyses have suggested that aspirin may be effective for the prevention of venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism) after total hip or total knee arthroplasty, but comparisons...

Added 11 months ago

Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients

Venous thromboembolism (VTE) is a potential cause of morbidity and mortality in patients after major orthopaedic surgery. Based on the...

Added 3 years ago

Intravenous Levosimendan and Vasopressin in New-Onset Acute Pulmonary Hypertension After Weaning from Cardiopulmonary Bypass.

Objective: A novel treatment with intravenous levosimendan and vasopressin for new-onset acute pulmonary hypertension after weaning from cardiopulmonary bypass is described.

Added 3 months ago

Load more

View all 12845 Journal articles items
Guidelines

2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management

These Guidelines are intended for physicians and collaborators involved in the pre-operative, operative, and post-operative care of patients undergoing non-cardiac surgery.

Added 4 years ago

Prevention and management of venous thromboembolism

The guideline identifies adult patient groups at risk of venous thromboembolism and describes the available methods of prophylaxis, with general recommendations about efficacy, safety, and how they should be used.

Added 8 years ago

Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

VTE is a condition in which a blood clot (thrombus) forms in a vein. It most commonly occurs in the...

Added 9 years ago

Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures

This guideline covers preventing infective endocarditis (IE) in children, young people and adults.

Added 10 years ago

2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction

Treatment with amiodarone is associated with changes in thyroid function tests, but also with thyroid dysfunction (amiodarone-induced hypothyroidism, AIH, and amiodarone-induced thyrotoxicosis, AIT).

Added 7 months ago

Load more

View all 1443 Guidelines items

More information

Category Value
Agency product number EMEA/H/C/000882
Orphan designation No
Date First Approved 21-02-2008
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Teva Pharma B.V.